WHAT IS CLAIMED IS:

1. A pharmaceutical composition, comprising:

(a) at least one pharmaceutically active agent that is pH dependent, said pharmaceutically active agent being selected from the group consisting of guanfacine and guanfacine hydrochloride;

(b) at least one non-pH dependent sustained release agent selected from the group consisting of ethylcellulose, cellulose acetate, vinyl acetate/vinyl chloride copolymers, acrylate/methacrylate copolymers, polyethylene oxide, hydroxypropyl methylcellulose, carrageenan, alginic acid and salts thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, karaya gum, acacia gum, tragacanth gum, locust bean gum, guar gum, sodium carboxymethyl cellulose, methyl cellulose, beeswax, carnauba wax, cetyl alcohol, hydrogenated vegetable oils, and stearyl alcohol; and

(c) at least one pH dependent agent that increases the rate of release of said at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5.

2. The composition of claim 1 wherein said at least one pH-dependent agent is at least one polymer that swells at a pH in excess of 5.5.

3. The composition of claim 2 wherein said at least one polymer that swells at a pH in excess of 5.5 is selected from the group consisting of acrylic acid copolymers, sodium alginate, carrageenan, alginic acid, pectin, and sodium carboxymethyl cellulose.

4. The composition of claim 1 wherein said at least one pH-dependent agent is at least one enteric agent.

5. The composition of claim 4 wherein said at least one enteric agent is selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate,

polyvinyl acetate phthalate, methacrylic acid copolymers, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate, succinate, shellac, and zein.

6. A pharmaceutical composition, comprising:

(a) at least one pharmaceutically active agent that is pH dependent, said pharmaceutically active agent being selected from the group consisting of anagrelide and anagrelide hydrochloride;

(b) at least one non-pH dependent sustained release agent selected from the group consisting of ethylcellulose, cellulose acetate, vinyl acetate/vinyl chloride copolymers, acrylate/methacrylate copolymers, polyethylene oxide, hydroxypropyl methylcellulose, carrageenan, alginic acid and salts thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, karaya gum, acacia gum, tragacanth gum, locust bean gum, guar gum, sodium carboxymethyl cellulose, methyl cellulose, beeswax, carnauba wax, cetyl alcohol, hydrogenated vegetable oils, and stearyl alcohol; and

(c) at least one pH dependent agent that increases the rate of release of said at least one pharmaceutically active agent from the tablet at a pH in excess of 5.5.

7. The composition of claim 6 wherein said non-pH-dependent sustained release agent is polyethylene oxide.

8. The composition of claim 6 wherein said at least one pH-dependent agent is at least one enteric agent.

9. The composition of claim 8 wherein said at least one enteric agent is selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, methacrylic acid copolymers, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate, succinate, shellac, and zein.

10. The composition of claim 9 wherein said at least one enteric agent is a methacrylic acid copolymer.

11. The composition of claim 6 and further comprising a bulking agent.

12. The composition of claim 11 wherein said bulking agent is dibasic calcium phosphate.

13. The composition of claim 11 wherein said bulking agent is microcrystalline cellulose.

14. The composition of claim 6 and further comprising a lubricant.

15. The composition of claim 14 wherein said lubricant is glyceryl behenate.

16. The composition of claim 14 wherein said lubricant is magnesium stearate.

17. A pharmaceutical composition, comprising:

(a) anagrelide;

(b) polyethylene oxide;

(c) dibasic calcium phosphate;

(d) microcrystalline cellulose;

(e) a methacrylic acid copolymer;

(f) glyceryl behenate; and

(g) magnesium stearate.

18. A pharmaceutical composition, comprising:

(a) Anagrelide hydrochloride;

(b) polyethylene oxide;

(c) dibasic calcium phosphate;

(d) microcrystalline cellulose;

(e) a methacrylic acid copolymer;

(f) glyceryl behenate; and

(g) magnesium stearate.

19. A method of treating a myeloproliferative blood disorder in a patient, comprising: administering to said patient the composition of Claim 6 in an amount effective to treat said myeloproliferative blood disorder in said patient.

20. The method of Claim 19 wherein said myeloproliferative blood disorder is essential thrombocythemia.

21. The method of Claim 19 wherein said myeloproliferative blood disorder is chronic myelogenous leukemia.

22. The method of Claim 19 wherein said myeloproliferative blood disorder is polycythemia vera.

23. The method of Claim 19 wherein said myeloproliferative blood disorder is agnogenic myeloid metaplasia.

24. The method of Claim 19 wherein the amount of the active ingredient anagrelide is about 0.01 mg to about 15 mg.

25. The method of Claim 19 wherein the amount of the active ingredient anagrelide is about 0.1 mg to about 10 mg.

26. The method of Claim 19 wherein the amount of the active ingredient anagrelide is about 0.1mg to about 5 mg.

27. The method of Claim 19 wherein the amount of the active ingredient anagrelide is about 0.5mg to about 2 mg.

28. A pharmaceutical composition comprising anagrelide as an active agent and characterized in that said composition when administered to a patient produces less of the side effects usually associated with anagrelide.

29. The pharmaceutical composition of claim 28 wherein said side effects are chosen from Headache, Asthenia, Somnolence , Dizziness, Tacchycardia , Nausea, Abdominal Pain, Vomiting, Infections or Palpitations.

30. The pharmaceutical composition of claim 29 wherein said side effects are chosen from Headache and Asthenia.

31. The pharmaceutical composition of claim 30 wherein said side effect is Headache.

32. The pharmaceutical composition of claim 30 wherein said side effect is Asthenia.

33. A method of reducing the likelihood of side effects associated with the administration of anagrelide, comprising administering to a patient a therapeutically effective amount of a composition as defined in claim 6.

34. The method of claim 33 wherein said side effects are chosen from Headache, Asthenia, Somnolence , Dizziness, Tacchycardia , Nausea, Abdominal Pain, Vomiting, Infections, or Palpitations.

35. The method of claim 34 wherein said side effects are chosen from Headache and Asthenia.

36. The method of claim 35 wherein said side effect is Headache.

37. The method of claim 35 wherein said side effect is Asthenia

38. A pharmaceutical composition, comprising:

(a) guanfacine;

(b) Hydroxypropyl Methylcellulose

(c) Ammonio Methacrylate Copolymer

(d) microcrystalline cellulose;

(e) a methacrylic acid copolymer;

(f) glyceryl behenate;

(g) Fumaric Acid,

(h) Lactose Monohydrate

(i) Povidone; and

(j) Crospovidone Granulated Blend.

39. A pharmaceutical composition comprising:

(a) Guanfacine hydrochloride;

(b) Hydroxypropyl Methylcellulose

(c) Ammonio Methacrylate Copolymer

(d) microcrystalline cellulose;

(e) a methacrylic acid copolymer;

(f) glyceryl behenate;

(g) Fumaric Acid,

(h) Lactose Monohydrate

(i) Povidone; and

(j) Crospovidone Granulated Blend.

40. A method of treating an attention deficit disorder or attention deficit with hyperactivity disorder in a patient, comprising administering to said patient the composition of Claim 1 in an amount effective to treat said attention deficit disorder or attention deficit with hyperactivity disorder in said patient.

41. A method of reducing the likelihood of side effects associated with the administration of guanfacine, comprising administering to a patient a therapeutically effective amount of the composition of Claim 1.